Second Tanta

This clinical trial focuses on evaluating how different 3D printing angles and layer thicknesses affect the fit, accuracy, and patient satisfaction of maxillary complete dentures in patients who have lost all their upper teeth. The study involves adults aged 50 to 70 with complete edentulism who require new maxillary and mandibular dentures. Researchers aim to identify the best 3D printing settings for making these dentures by comparing three build orientations 0, 45, and 90. Participants will receive two maxillary dentures made using the same printing orientation but with two different layer thicknesses 50 micrometers and 100 micrometers in a crossover design. Each denture will be worn for three months before switching to the other. The study groups are based on the printing angle used 0, 45, or 90. The accuracy of the dentures is measured by scanning and comparing the printed dentures to the original digital designs. During the study, participants will be assessed on how true to the design the dentures are, how much the dentures change dimensionally over three months, and their satisfaction based on comfort, speech, chewing efficiency, hygiene, and appearance. Satisfaction is measured using a Visual Analogue Scale shortly after insertion and again after three months of use. The study will last about six months per participant, covering both denture wear periods.

Researchers are investigating the safety, compliance, and effectiveness of different bowel preparation methods before colonoscopy. This randomized controlled trial compares three regimens a 4-liter split-dose polyethylene glycol combined with bisacodyl and docusate sodium, a 2-liter split-dose polyethylene glycol plus oral simethicone, and a conventional 2-liter split-dose polyethylene glycol alone. The study aims to assess how well these methods prepare the bowel and their tolerability for patients undergoing colonoscopy. Participants will be randomly assigned to one of three groups. One group receives four sachets of polyethylene glycol mixed in 4 liters of water over 8 hours starting at 9 a.m., along with bisacodyl and docusate sodium tablets. The second group receives two sachets of polyethylene glycol mixed in 2 liters of water over 4 hours from 9 a.m. plus oral simethicone tablets. The third group receives two sachets of polyethylene glycol in 2 liters of water over 4 hours starting at 9 a.m. without simethicone. Colonoscopy is performed 24 hours after starting the preparation. During the study, participants will undergo medical history taking, clinical exams, laboratory tests, and colonoscopy. Researchers will evaluate the quality of bowel preparation using the Aronchick scale, monitor adverse events, and collect patient feedback on ease of use, tolerability, and willingness to repeat the same regimen in the future. The primary outcome is completing a full colonoscopy successfully, with safety and tolerability tracked throughout the study period, which lasts about one year.

Diffuse large B-cell lymphoma DLBCL is the most common and aggressive subtype of non-Hodgkin lymphoma, with rapid tumor growth and symptoms varying by tumor location. The disease is classified using advanced methods like immunohistochemistry and molecular testing to guide prognosis and personalized treatment. Despite standard immunochemotherapy curing 60-70% of patients, many experience treatment failure or relapse, and options after second-line therapies remain limited. This observational study examines treatment patterns, demographic, and clinical characteristics of DLBCL patients in the Middle East and Africa. It includes two patient groups those newly diagnosed and eligible for treatment, and those with relapsed or refractory DLBCL who have failed previous therapies. The study aims to explore access to novel therapies and understand real-world treatment approaches in these regions. Participants will be observed over 22 months, during which researchers will document treatment regimens, patient risk profiles, and access to new treatments. Data collection includes patient demographics, disease characteristics, and treatment outcomes. The study does not involve experimental treatments but gathers detailed information to inform future care strategies for DLBCL patients.

This research aims to compare the safety and effectiveness of three different endoscopic techniques for removing large prostate tissue in men with benign prostatic hyperplasia BPH who experience severe urinary symptoms. The study focuses on men with prostate sizes over 100 mL who have not responded to medical treatments and have significant symptoms measured by the International Prostate Symptom Score IPSS and urinary flow rates. The trial is a prospective randomized controlled study conducted at Tanta University Hospital, evaluating three surgical methods used to treat large prostates causing lower urinary tract symptoms. Participants will be randomly assigned to one of three groups, each undergoing a different prostate enucleation procedure Thulium Fiber Laser Enucleation ThuFLEP using a 60W thulium fiber laser, Holmium Laser Enucleation HoLEP using a 150W holmium YAG laser, or Bipolar Transurethral Enucleation B-TUEP using bipolar electrical energy. All procedures are performed transurethrally and involve removing the prostate tissue with a morcellator. Each group will have 30 patients, and the study will run from October 2025 to October 2027. Participants will undergo thorough preoperative assessments including symptom scores, urinary flow tests, ultrasounds, blood tests, and prostate-specific antigen measurements. After surgery, follow-ups at 1, 3, and 6 months will evaluate symptom relief, quality of life, urinary flow rate, residual urine volume, and erectile function. Researchers will also track operative times, blood loss, catheter duration, hospital stay, and complications categorized by the Clavien-Dindo system. The study measures both patient outcomes and surgical efficiency over six months post-operation.

This research aims to evaluate whether alveolar bone decortication combined with concentrated growth factor CGF injection can speed up tooth movement during orthodontic treatment, specifically focusing on the retraction of the maxillary canine. The study involves patients aged 16 to 22 years with certain types of malocclusion requiring extraction and canine retraction, seeking to understand the impact of this combined procedure on accelerating orthodontic tooth movement. Participants will receive treatment on one side of the upper jaw that includes alveolar decortication followed by CGF injection near the maxillary canine. This surgical procedure involves making multiple small perforations in the cortical bone after local anesthesia and flap reflection, followed by CGF injection. The other side of the upper jaw will receive standard orthodontic canine retraction without acceleration techniques, serving as the control. The procedure is randomized and single-blinded. During the 4-month study period, researchers will measure the rate of canine retraction as the primary outcome. Participants will undergo regular orthodontic treatment visits, and the study will monitor the difference between the treated and control sides. The study also includes assessment of oral hygiene and periodontal health to ensure suitability and safety throughout treatment. Overall participation spans the tooth movement period, with close follow-up to observe effects of the intervention.

Researchers are comparing the effectiveness and safety of three add-on drugsempagliflozin, acetazolamide, and metolazonewhen given with loop diuretics to patients hospitalized with acute decompensated heart failure. This phase 2 clinical trial aims to understand which of these treatments best supports fluid removal and heart failure management in this patient group. The study includes three groups of 22 patients each. One group receives 10 mg of empagliflozin, another 500 mg of acetazolamide, and the third 5 mg of metolazone. Each drug is given orally alongside the first dose of loop diuretics daily for three days. The trial does not use placebos and participants are randomly assigned to one of the three treatment groups. Participants will be closely monitored during the three-day treatment period with measurements such as total urine output and changes in specific blood and urine biomarkers related to heart failure. Researchers will also track 30-day mortality rates and assess treatment effectiveness using the ADVOR Score. This monitoring helps evaluate the safety and impact of these add-on therapies over the short term and up to 30 days after treatment begins.

This research aims to evaluate the effect of adding calcitonin to bupivacaine during an ultrasound-guided transversalis fascia plane block for women undergoing cesarean section. The study is a prospective randomized trial designed to compare pain relief methods in this surgical setting.

This research aims to evaluate whether guiding pressure support ventilation using Airway Occlusion Pressure P0.1 is better than conventional management for patients in the weaning window from mechanical ventilation. The study focuses on critically ill adults with acute respiratory failure who are transitioning from assisted ventilation toward spontaneous breathing. It highlights the importance of optimizing ventilator weaning to reduce risks like lung injury and diaphragm dysfunction. Participants will be randomly assigned to one of two groups. One group will receive conventional pressure support ventilation based on clinical assessment, while the other group will have pressure support ventilation guided by P0.1 measurements, which assess the patients respiratory drive more directly. The study monitors treatment effects over time, focusing on ventilator-free days and other important clinical outcomes. During the trial, participants will be closely monitored for respiratory status, sedation levels, and hemodynamic stability. Assessments include measuring ventilator-free days by day 28, duration of mechanical ventilation until successful extubation, length of ICU stay, patient-ventilator synchrony, sedation drug requirements, and weaning success. The study involves regular clinical evaluations to track these outcomes and ensure participant safety throughout the treatment period.

Researchers are evaluating the efficacy and safety of alpha-lipoic acid combined with mesalamine in patients with mild to moderate ulcerative colitis. This study focuses on alpha-lipoic acids antioxidant and anti-inflammatory properties, which may help improve the condition. The trial is designed as a randomized, single-blind study led by Tanta University. Participants will be randomly assigned to one of two groups. One group receives mesalamine 1000 mg three times daily plus a placebo once daily, while the other group receives mesalamine 1000 mg three times daily plus alpha-lipoic acid 600 mg once daily. The treatment lasts for three months. During the study, participants will be monitored for changes in health-related quality of life and disease severity after three months of treatment. Biological markers such as fecal calprotectin, reduced glutathione, interleukin-6, and transforming growth factor-beta 1 will also be measured. The study includes regular assessments to track safety and effectiveness throughout the treatment period.

Researchers are comparing the pain relief effects of a multiple mid-transverse process to pleura MTP block with patient-controlled analgesia PCA using morphine in adults with idiopathic scoliosis undergoing posterior spinal fusion surgery. The study addresses the challenges of managing postoperative pain and hospitalization length in this group. Regional anesthesia techniques like epidural analgesia and paravertebral blocks, enhanced by ultrasound guidance, have become important in multimodal pain management. The MTP block and erector spinae plane ESP block are newer methods being evaluated for postoperative pain control. Participants are randomly assigned to one of two groups. One group receives multiple MTP blocks after anesthesia induction. The other group uses intravenous PCA with morphine, starting with a loading dose before surgery ends, followed by patient-controlled doses with specified lockout intervals and background infusion rates. This randomized, double-blind trial compares these two pain management approaches during and after surgery. Throughout the study, researchers monitor pain levels 24 hours after surgery as the primary outcome. They also track intraoperative fentanyl use, timing of first rescue analgesia, total morphine use, blood pressure and heart rate every 15 minutes during surgery, patient satisfaction, and any complications within 24 hours postoperatively. The overall goal is to better understand and improve pain control strategies in scoliosis surgery patients.